SunTrust analyst Sandy Draper lowered his price target on HealthEquity to $80 after its below-consensus FY19 guidance update last week. The analyst notes that while the EBITDA margins expectations for its recently acquired WageWorks should be beatable, he is concerned about the adverse impact of the current interest rate environment persisting through at least the end of next year. Draper is keeping his Buy rating on HealthEquity stock longer term however, noting that investors may be overlooking the company's "cushion" given its spread on custodian AUM and also believes that upside in the stock price can come from improved RFP conversion rates.